Understanding the impact of targeting the epigenetic regulation of lung stem cells in congenital lung disease
了解针对肺干细胞表观遗传调控对先天性肺病的影响
基本信息
- 批准号:10726411
- 负责人:
- 金额:$ 16.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AffectBasal CellCause of DeathCellsComplexCongenital AbnormalityCongenital diaphragmatic herniaDNA Sequence AlterationDefectDevelopmentDiseaseEngineeringEpigenetic ProcessEpitheliumGenesGeneticGenetic TranscriptionGenomicsGrowthHealthHerniaIndividualInterventionLifeLong-Term CareLungLung diseasesLysineMapsMeasuresMediatingMethyltransferaseMutateMutationNewborn InfantOperative Surgical ProceduresOrganPathogenicityPatientsPharmacologic SubstanceProgram DevelopmentRegulator GenesStructureSurvivorsTestingTracheaVariantaspiratecohortdesigndevelopmental diseaseepigenetic regulationgenetic varianthistone demethylasehistone methyltransferaseinhibitorloss of functionlung developmentmortalitynew technologyprematureprogenitorrecruitrepairedself-renewalstem cell self renewalstem cellstherapy developmenttranscriptomics
项目摘要
Project Summary
Congenital lung diseases are serious disorders which prematurely end the lives of many and place large health
burdens on surviving individuals throughout their lives. Congenital Diaphragmatic Hernia (CDH) is one such
disease which causes severe underdevelopment (hypoplasia) of the lung. Although the hernia can be
surgically repaired, the lung defects are persistent, leading to high mortality and complicated long-term care for
survivors. There are many genetic factors contributing to CDH, and some of these genes change lung
development independently from the effects of the hernia, showing their intrinsic importance to the normal
growth of the lung. Through a synthesis of genomic and transcriptomic analyses of CDH patients we have
identified two genes, KMT2D and KDM6A as strong candidates to mediate the severe lung hypoplasia. KMT2D
(Lysine Methyltransferase 2D) and KDM6A (Lysine Demethylase 6A) are co-operating epigenetic regulators
which can be both mutated and downregulated in CDH and are known to be important to stem cells. New
technological advances have allowed us to isolate lung epithelial basal stem cells from the tracheal aspirates
of recruited CDH and control patients. We will utilize these cells to test if the loss of function of these epigenetic
regulators affects the ability of these cells to self-renew and generate differentiated lung epithelium, and to
identify the downstream genes which they control. Our specific aims are 1) Determine the effects of pathogenic
KMT2D/KDM6A genetic variants and pharmaceutical interventions on the differentiation/self-renewal of patient-
derived lung basal stem cells derived from tracheal aspirates, and 2) Map the H3K4me1 and H3K27me3
epigenetic changes in CDH and control basal stem cells following mutation or inhibition of KMT2D/KDM6A.
With this approach we will be taking advantage of the genetic breakthroughs in CDH to make discoveries that
are potentially relevant to a whole class of lung diseases. These aims will help us understand how the
mechanisms governing lung development go awry and enable us to develop therapies to correct these
problems.
项目概要
先天性肺病是一种严重的疾病,它会过早地结束许多人的生命并损害人们的健康
幸存者一生的负担。先天性膈疝(CDH)就是其中之一
导致肺部严重发育不良(发育不全)的疾病。虽然疝气可以
经过手术修复后,肺部缺陷持续存在,导致高死亡率和复杂的长期护理
幸存者。导致 CDH 的遗传因素有很多,其中一些基因会改变肺部
发育独立于疝气的影响,显示出其对正常生命的内在重要性
肺部的生长。通过对 CDH 患者的基因组和转录组分析进行综合分析,我们发现
确定了两个基因 KMT2D 和 KDM6A 作为介导严重肺发育不全的有力候选基因。 KMT2D
(赖氨酸甲基转移酶 2D)和 KDM6A(赖氨酸脱甲基酶 6A)是协同作用的表观遗传调节因子
它可以在 CDH 中突变和下调,并且已知对干细胞很重要。新的
技术进步使我们能够从气管吸出物中分离出肺上皮基底干细胞
招募的 CDH 患者和对照患者。我们将利用这些细胞来测试这些表观遗传功能是否丧失
调节因子影响这些细胞自我更新和生成分化肺上皮的能力,并
识别它们控制的下游基因。我们的具体目标是 1) 确定致病因素的影响
KMT2D/KDM6A 基因变异和药物干预对患者分化/自我更新的影响
源自气管抽吸物的肺基底干细胞,以及 2) 绘制 H3K4me1 和 H3K27me3 的图谱
KMT2D/KDM6A 突变或抑制后 CDH 和控制基底干细胞的表观遗传变化。
通过这种方法,我们将利用 CDH 的遗传突破来做出以下发现:
可能与一整类肺部疾病相关。这些目标将帮助我们了解如何
控制肺部发育的机制出错,使我们能够开发出纠正这些机制的疗法
问题。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Samuel Philip Rowbotham其他文献
Samuel Philip Rowbotham的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Map the human airway basal cell niche and the role that FGFR2 plays within it
绘制人类气道基底细胞生态位图以及 FGFR2 在其中发挥的作用
- 批准号:
10752101 - 财政年份:2023
- 资助金额:
$ 16.7万 - 项目类别:
Ancillary SOURCE Study: Characterization of Small Airway Basal Cell Biology in Early COPD
辅助来源研究:早期 COPD 中小气道基底细胞生物学的特征
- 批准号:
10736644 - 财政年份:2023
- 资助金额:
$ 16.7万 - 项目类别:
Precision oncology to define basal cell carcinoma (BCC) with high-risk histopathological subtypes
精准肿瘤学定义具有高风险组织病理学亚型的基底细胞癌 (BCC)
- 批准号:
485125 - 财政年份:2023
- 资助金额:
$ 16.7万 - 项目类别:
Operating Grants
Analysis of intraoperative videos from basal cell carcinoma removal surgery
基底细胞癌切除手术术中视频分析
- 批准号:
574060-2022 - 财政年份:2022
- 资助金额:
$ 16.7万 - 项目类别:
University Undergraduate Student Research Awards
Mechanisms of Basal Cell Dysfunction in Chemical-induced Bronchiolitis Obliterans
化学诱发闭塞性细支气管炎基底细胞功能障碍的机制
- 批准号:
10693404 - 财政年份:2022
- 资助金额:
$ 16.7万 - 项目类别:
Mechanisms of Basal Cell Dysfunction in Chemical-induced Bronchiolitis Obliterans
化学诱发闭塞性细支气管炎基底细胞功能障碍的机制
- 批准号:
10523626 - 财政年份:2022
- 资助金额:
$ 16.7万 - 项目类别:
Developing Improved Models of Basal Cell Carcinoma to Evaluate Tumor-Drug Response
开发改进的基底细胞癌模型以评估肿瘤药物反应
- 批准号:
10518702 - 财政年份:2022
- 资助金额:
$ 16.7万 - 项目类别:
Optimization of topical formulations for the treatment of basal cell carcinoma using the Feldan Shuttle technology
使用 Feldan Shuttle 技术优化治疗基底细胞癌的局部制剂
- 批准号:
549971-2020 - 财政年份:2022
- 资助金额:
$ 16.7万 - 项目类别:
Applied Research and Development Grants - Level 3
Predicting drug response for basal cell carcinoma by comprehensive genomic analysis.
通过综合基因组分析预测基底细胞癌的药物反应。
- 批准号:
21K16898 - 财政年份:2021
- 资助金额:
$ 16.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Optimization of topical formulations for the treatment of basal cell carcinoma using the Feldan Shuttle technology
使用 Feldan Shuttle 技术优化治疗基底细胞癌的局部制剂
- 批准号:
549971-2020 - 财政年份:2021
- 资助金额:
$ 16.7万 - 项目类别:
Applied Research and Development Grants - Level 3














{{item.name}}会员




